^
Association details:
| Biomarker: | ABCG2 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | topotecan (Topoisomerase I inhibitor) + nuvisertib (TP-3654) (PIM-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
Published date:
08/30/2021
Excerpt:
In this study, we discovered that by attenuating the drug transport function of ABCG2, TP-3654 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic ABCG2 substrate drugs topotecan, SN-38 and mitoxantrone....Taken together, our findings reveal that TP-3654 is a selective, potent modulator of ABCG2 drug efflux function that may offer an additional combination therapy option for the treatment of multidrug-resistant cancers.
DOI:
10.3390/ijms22179440
